mattress capit deploy could drive upsid
invest summari beat reiter overweight rate
price target multipl expans upward earn revis
drive share higher view think upsid earn
driven smart capit deploy grow cash flow
think much increas assum deploy
guidanc past note priorit use cash
follow re-invest base busi a/busi develop
posit quarter support thesi chca achiev
sale growth yoy constant currenc basi
busi sale grew yoy constant currenc basi rx realiz
report oper margin segment extend topic
strategi deliv adjust oper margin cash
flow oper
report ep factset consensu
higher estim ep guidanc factset
consensu updat financi model
report outlook decreas ep estim
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
sever potenti risk posit invest thesi price target
gener drug price stabil goe downsid risk
entir gener industri custom consolid creat greater leverag buy
consortium extract price concess gener compani
gener consolid may make harder compet small mid-siz
gener compani need consolid stay competit market custom
increas buy power competitor get bigger stay could
make hard compet industri
competit perrigo over-the-counter product europ could neg effect
market share price could make hard meet financi
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario estim likelihood share price
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casegrow chc sale industryomega turnaround better expecteddebt paydown better expectednew launch better expectedflea tick cough cold allergi season better scenario casegrow chc sale industryomega turnaround in-lin expectationsdebt paydown in-lin expectationsnew launch in-lin expectationsflea tick cough cold allergi season in-lin scenario casegrow chc sale industryomega turnaround expectationsdebt paydown expectationsnew launch expectationsflea tick cough cold allergi season scenario exhibit varianc analysi
amount chang yoyamount chang yoyvariancecommentstot growth chca gastrointestin analges new product sale nexium smoke cessat product gross lower sell expens due previous announc restructur oper oper non oper pre-tax tax net averag oper cantor fitzgerald research compani estim exhibit catalyst event calendar
datedriverupcom day pend approv gener per settlementl hfalaunch per settlement agreement singl entityresolv excipi issu re-launch per settlement brimonidin topic gel stay stay expiresearli stay foam stay launch gener launch gener per settlementsourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
mm except per share amount guidancemidpointestimatesnet net net expens effect tax dilut ep share healthcar healthcar cantor fitzgerald research compani expect report dilut ep rang expect report oper incom rang expect report effect tax rate expect new product launch total sale adjust oper margin three busi segment expect line last expect rx sale growth assum high singl digit price eros includ two product launch one assum proair contribut oper incom sequenti improv oper incom driven new product launch exhibit incom statement analysi
million except ep compound-annual-growth-rate year end decemb incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnminterest cantor fitzgerald research compani report exclud acquisition-rel amort integration-rel charg restructur charg collabor payment omega acquisit relat expens equiti method invest loss relat tax effect exclud acquisition-rel amort collabor arrang payment restructur charg omega acquisit integration-rel expens increas litig accrual loss deriv incom transfer right agreement equiti method invest loss bridg fee extinguish debt weight averag effect share issu novemb financ omega acquisit escrow settlement relat sergeant acquisit integration-rel charg litig settlement million net write-up conting consider write-off ipr relat paddock rosemont acquisit transact cost extinguish debt intang asset impair loss sale invest acquisition-rel cost take-over defens fee tax effect non-gaap adjust exclud acquisition-rel amort expens oper result attribut held-for-sal vm india api busi acquisit integration-rel expens restructur relat fee intang asset goodwil impair charg relat bch segment loss equiti method invest loss earli extinguish debt tax effect non-gaap adjust non-oper chang defer tax item effect use tax attribut exclud amort expens relat acquir intang asset chang financi asset loss earli debt extinguish restructur charg impair charg oper result held sale busi tysabri royalti stream acquisit integr expens gains-to-loss ondivestitur unusu litig tax effect adjust exhibit margin analysi
year end decemb cantor fitzgerald research compani report exhibit quarterli sale analysi
million year end decemb healthcar healthcar changeconsum healthcar healthcar cantor fitzgerald research compani report exhibit annual sale analysi
sale base new product anim healthallegra corticosteroid flonas disclos new product anim risk adjust new product healthcar acquisitionsgalpharm brand healthcar consum sale base paragraph iv gener piv piv piv hfa risk-adjust us paragraph iv rx cantor fitzgerald research compani reportsnot bold identifi paragraph iv opportun mean settl launch date pbm nutrit sale consum base busi end decemb
exhibit analysi
million decemb fiscal oper activitiesnet depreci net chang work capit net invest activitiespurchas acquisit intangibles- purchas proce market secur net financ activitiespay issuanc purchas treasuri stock- proce option employe stock purchases- dividend net /equiv balanc net /equiv balanc sourc cantor fitzgerald research compani report exhibit balanc sheet analysi
million decemb fiscal current intang sharehold equityaccount accru portion long term current term paid common stock treasuri sharehold liabil sharehold cantor fitzgerald research compani report march
diversifi store brand brand consum rx pharmaceut compani believ continu
market leader store brand brand consum drug forese futur
